Cellics Therapeutics
San Diego, US · Founded 2014 · Delaware corporation
Cellics Therapeutics is a therapeutics company; its website is a placeholder page providing only contact and location details, with no description of its products or focus.
Biotech
Founders & leadership
HZ
Huiqing ZhuExecutive
LX
Lili XieExecutive
Board
DJ
Dai JinmingBoard director
Reported raises · per SEC filings
Form D private placements$33M disclosed across 4 rounds · 2016–2022
▶$7MraisedFeb 2022 · 1 investors · BiotechnologyRule 506(b)
▶$7MraisedFeb 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Cihui LiDirector
- Angela Fang ChenDirector
- Liangfang ZhangDirector
- Lili XieExecutive Officer
- Wei ShenDirector
- Jie ZhangExecutive Officer, Director
- Offering amount
- $25M
- Amount sold
- $7M
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13MraisedJun 2020 · 3 investors · BiotechnologyRule 506(b)
▶$13MraisedJun 2020 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Huiqing ZhuExecutive Officer
- Lili XieExecutive Officer, Director
- Angela Fang ChenDirector
- Dai JinmingDirector
- Weiwei GaoDirector
- Offering amount
- $13M
- Amount sold
- $13M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7MraisedApr 2018 · 4 investors · BiotechnologyRule 506(b)
▶$7MraisedApr 2018 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dai JinmingDirector
- Huiqing ZhuExecutive Officer, Director
- Lili XieExecutive Officer, Director
- Offering amount
- $7M
- Amount sold
- $7M
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$6MraisedApr 2017 · 1 investors · BiotechnologyRule 506(b)
▶$6MraisedApr 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Huiqing ZhuExecutive Officer, Director
- Dai JimmingDirector
- Lili XieExecutive Officer, Director
- Offering amount
- $6M
- Amount sold
- $6M
- First sale
- Feb 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlapKite Pharma12 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Linkcelltx9 shared keywordsLink Cell Therapies develops CAR T cell therapies using logic-gate ("AND-gate") technology that requires co-expression of cancer targets to increase specificity for tumors. The company targets solid tumors and certain hematologic cancers.
Cellectis8 shared keywordsCellectis is a gene-editing company that uses its TALEN technology to engineer CAR T-cells from healthy donors into "off-the-shelf" allogeneic immunotherapy candidates aimed at treating cancer and potentially other diseases. It develops therapies designed to be broadly available rather than custom-made per patient.
Celldex Therapeutics, Inc.7 shared keywordsCelldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation. The page shown is a board director biography rather than a company overview.
Lyell7 shared keywordsLyell is a clinical-stage biotech developing next-generation CAR T-cell product candidates intended as one-time treatments for patients with cancer, targeting both hematologic malignancies and solid tumors. The company owns and operates its own manufacturing facility to control its cell therapy supply chain.
Solu6 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies competing with Cellics Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Cellics Therapeutics do?
- Cellics Therapeutics is a therapeutics company; its website is a placeholder page providing only contact and location details, with no description of its products or focus.
- How much funding has Cellics Therapeutics raised?
- Cellics Therapeutics has disclosed $33M raised across 4 rounds.
- Where is Cellics Therapeutics headquartered?
- Cellics Therapeutics is headquartered in San Diego, US.